Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
253.9 USD | +0.46% | -1.82% | +9.72% |
Mar. 15 | Lilly weight-loss drug Zepbound new US prescriptions surpass Wegovy for first time | RE |
Mar. 14 | Transcript : IQVIA Holdings Inc. - Special Call |
Financials (USD)
Sales 2024 * | 15.54B | Sales 2025 * | 16.67B | Capitalization | 46.21B |
---|---|---|---|---|---|
Net income 2024 * | 1.33B | Net income 2025 * | 1.58B | EV / Sales 2024 * | 3.75 x |
Net Debt 2024 * | 12.07B | Net Debt 2025 * | 11.65B | EV / Sales 2025 * | 3.47 x |
P/E ratio 2024 * |
34.7
x | P/E ratio 2025 * |
29.1
x | Employees | 87,000 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 70.18% |
Latest transcript on Iqvia Holdings Inc.
1 day | +0.46% | ||
1 week | -1.29% | ||
Current month | +2.71% | ||
1 month | +6.40% | ||
3 months | +11.98% | ||
6 months | +19.91% | ||
Current year | +9.72% |
Managers | Title | Age | Since |
---|---|---|---|
Ari Bousbib
CEO | Chief Executive Officer | 62 | 16-10-02 |
Ronald Bruehlman
DFI | Director of Finance/CFO | 63 | 20-07-31 |
James Berkshire
COO | Chief Operating Officer | 51 | 17-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Danhakl
BRD | Director/Board Member | 67 | 16-10-02 |
Colleen Goggins
BRD | Director/Board Member | 68 | 17-07-26 |
Ari Bousbib
CEO | Chief Executive Officer | 62 | 16-10-02 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.67% | 0 M€ | 0.00% | - | |
3.45% | 0 M€ | 0.00% | - | |
2.92% | 1 M€ | -.--% | - | |
2.68% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-03-18 | 253.9 | +0.46% | 733,668 |
24-03-15 | 252.7 | -0.61% | 1,139,793 |
24-03-14 | 254.3 | -0.54% | 989,184 |
24-03-13 | 255.6 | -1.33% | 812,997 |
24-03-12 | 259.1 | +0.20% | 839,113 |
Delayed Quote Nyse, March 18, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.72% | 46B | |
+35.14% | 39.85B | |
+4.84% | 39.76B | |
-9.43% | 28.16B | |
+17.47% | 27.62B | |
-22.99% | 18.8B | |
+10.88% | 13.3B | |
+27.53% | 12.2B | |
-6.84% | 11.4B | |
+6.40% | 11.1B |